DOCSLIB.ORG

Incidence and Pathogenesis of Megaloblastic Erythropoiesis in Multiple Myeloma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Incidence and Pathogenesis of Megaloblastic Erythropoiesis in Multiple Myeloma J Clin Pathol: first published as 10.1136/jcp.20.5.699 on 1 September 1967. Downloaded from J. clin. Path. (1967), 20, 699 Incidence and pathogenesis of megaloblastic erythropoiesis in multiple myeloma A. V. HOFFBRAND,1 J. R. HOBBS, S. KREMENCHUZKY, AND D. L. MOLLIN From the Departments of Haematology and Chemical Pathology, Royal Postgradute Medical School, Ducane Road, London, and the Medical Research Council Group for Investigation into Megaloblastic and Sideroblastic Anaemias SYNOPSIS Intermediate megaloblastic changes occurred in six (19 %) of 32 patients with multiple myeloma and trivial megaloblastic changes in a further ten (31 %). Folate deficiency was the pre- dominant cause of these changes and in at least two patients was sufficiently severe to contribute to anaemia. Folate deficiency appeared to be due to excess folate utilization by the tumour and was related to the amount of paraprotein produced daily. Five of the 32 patients had subnormal serum B12 levels. Reduction in the serum B12 level was related to the reduction in the normal circulating immunoglobulins and occurred despite normal B12 absorption. Possible explanations for this finding are discussed. copyright. Subnormal serum vitamin B12 concentrations have Larsson, 1962; van Dommelen, Olie, and Slagboom, been reported in patients with multiple myeloma by a 1964). number of authors (Mollin and Ross, 1952; The present study was undertaken to determine the Mandema, 1956; Mandema, Faber, de Vries, and incidence, severity, and cause of B12 deficiency in Nieweg, 1956; Killander and Larsson, 1962; Larsson, patients with multiple myeloma. Since megaloblastic 1962; Forshaw, 1963; Hansen, 1964). In some ofthese anaemia in other conditions in which thereis prolifera- patients megaloblastic anaemia was also observed tion of primitive tissue is almost invariably due to http://jcp.bmj.com/ and in the patients of Mandema (1956), in two folate deficiency (Swendseid, Swanson, Meyers, and patients of Larsson (1962), and in the patient of Bethell, 1952; Girdwood, 1953), the incidence and Forshaw (1963) the anaemia responded to large pathogenesis of folate deficiency was investigated in doses of vitamin B12. The anaemia in another patient the same group of patients and this paper reports the of Larsson (1962) and the patient of Bichel (1964) results of both studies. responded to liver therapy. Nonetheless, true Addisonian pernicious anaemia PATIENTS STUDIED on September 26, 2021 by guest. Protected appears to be rare in myeloma and it has only been established by the demonstration of histamine-fast Thirty-two randomly selected patients with myeloma achlorhydria associated with malabsorption of were studied. Their ages ranged from 42 to 81 (mean 67 vitamin B12 corrected by intrinsic factor in three years) and they included 17 males and 15 females. All the cause patients were investigated while in hospital for inves- patients (cases 2,3, and 5 ofLarsson, 1962). The tigation or treatment. of subnormal serum B12 concentrations in patients In each patient, the diagnosis was made because the with myeloma without pernicious anaemia is un- patient showed clinical and/or radiological evidence of certain. It has been suggested that they are due to bone lesions ofthe myeloma type, abnormal and increased malabsorption of vitamin B12 associated with numbers of plasma cells in the bone marrow, a charac- bacterial contamination of the small intestine teristic narrow 'monoclonal' band on electrophoresis of (Larsson, 1962) or to excess B12 utilization by the the serum proteins and/or Bence-Jones proteinuria. Ten tumour (Mandema et al., 1956; Killander and patients were studied at the time myeloma was first diagnosed, and in the remaining 22 patients myeloma was 'Present address: Department of Haematology, St. Bartholomew's known to have been present from two months to nine Hospital, London E.C.1. years previously. Fifteen patients were receiving no specific Received for publication 29 March 1967. therapy, seven patients were receiving melphelan (from 699 J Clin Pathol: first published as 10.1136/jcp.20.5.699 on 1 September 1967. Downloaded from 700 A. V. Hoffbrand, J. R. Hobbs, S. Kremenchuzky, and D. L. Mollin 0-25 to 4 mg. daily), one patient urethane (3 mg. daily), myeloma globulins (mean 11-6 days) (Drivsholm, 1964). one patient prednisone (5 mg. b.d.), and eight were having For the same serum concentration, therefore, YA protein deep x-ray therapy for bone lesions. In the patients on has a faster turnover (estimated as 10-8 % ofthe total pool) cytotoxic drugs, serum for microbiological assay was than YG protein (estimated as 6% of the total pool). In taken at least 24 hours after the last dose of the drug. order to compare our patients, we have arbitrarily con- sidered them all to be 71 kg. in weight, with a plasma METHODS volume of 50 7 ml. per kg., with the plasma containing 71% of the total pool of myeloma globulin (averages of B12 CONCENTRATIONS These were deter- availabledatainmyeloma patients, Gabuzda, 1962). Thus, SERUM VITAMIN M g. mined by microbiological assay using the z strains of fora given serum concentration of myeloma globulin, Euglenagracilis as test organism as described by Anderson per 100 ml., the total pool would be M x 71 x 50-7 x (1964) with a normal range from 160 to 925 ,u.g. per ml. 100° = 50 7 M and for in the VITAMIN B12 ABSORPTION This was measured by the g., patients equilibrium, urinary excretion method of Schilling (1953) using an oral average daily productions of YA would be 10-8% of dose of 1 ,ug. radioactive "8Co-B12 and an intramuscular 50-7M = 5 5 Mg., andofyG6% of 50-7M = 30 Mg. flushing dose of 1,000 ,ug. non-radioactive B12. Normal In order to obtain the total daily M protein production, subjects excrete more than 10% ofthe oral dose in 24 hours the daily Bence-Jones protein loss in the urine was meas- and patients with Addisonian pernicious anaemia excrete ured, corrected to 71 kg. from the patient's body weight, less than 5% and usually less than 2-5 %in 24 hours. and added to the production of M protein, calculated above. SERUM FOLATE CONCENTRATIONS These were estimated by It is recognized that this calculation only gives an microbiological assay using Lactobacillus casei as test approximate value since plasma and total body pools and organism as described by Waters and Mollins (1961). The the half life of the plasma proteins all show individual normal range is from 6-0 to 21-0 mug. per ml. variation. Nevertheless, this variation is mostly less than ± 25% of the taken means. SERUM MYELOMA PARAPROTEINS These were recognized by their narrow 'monoclonal' electrophoretic mobility, or so- LOSS OF NORMAL HUMORAL IMMUNITY This was estimated copyright. called 'M' band. They were identified by immunoelectro- bymeasuringtheconcentrationof the serum immunoglob- phoresis as YG, yA, or Bence-Jones protein. Their light ulins (yG, YA, and YM) and taking their average, each chains were shown to be of one type only and identified expressed as a percentage of the normal mean, e.g., case as K (Kappa) or L (Lambda) (Nomenclature of Human FB had serum concentrations, YG 75%, YA 70%, and Immunoglobulins, Bull. Wld Hlth Org., 1964). YM 70% of normal, giving an average 72% of the normal immunoglobulin concentration. TOTAL SERUM PROTEIN CONCENTRATIONS These were esti- mated by a Biuret method calibrated against Armour HAEMATOLOGICAL FINDINGS standard bovine albumin. Using this method, YG globulin http://jcp.bmj.com/ yields 3% less colour, and YA globulin 8% less colour than INCIDENCE OF MEGALOBLASTIC HAEMOPOIESIS In the same weight of albumin but no correction has been Table I, patients are divided according to whether or made, the error being slight, since, in all but one patient, not they show megaloblastic change in the bone the concentration of myeloma (M) protein in the serum marrow. Six(19 %) ofthe 32 patients (group I) showed was less than half the total serum protein concentration. intermediatemegaloblasticchanges (DacieandWhite, The proportion of M protein in the serum proteins was 1949) and a further 10 (31 %) patients (group II) estimated after electrophoresis on cellulose acetate using showed trivial megaloblastic changes. The remaining the dye amidoschwarz lOB as colouring agent. This dye 16patients(groupIII) had entirely normoblastic bone on September 26, 2021 by guest. Protected yields near uniform uptakes for the same weights of the florid albumin, YG, and YA globulins and recoveries ofpure added marrows. None of the patients showed fractions are reliable to within 0-2 g. per 100 ml. (Hobbs, megaloblastic changes seen in severely anaemic 1965). The concentration of M protein was then calculated patients with uncomplicated megaloblastic anaemia. from the known total serum protein concentration. The appearances of the stained peripheral blood films were largely, but not invariably, consistent with URINARY PROTEIN was estimated by a Biuret method after these bone marrow findings. Macrocytes and hyper- ovemight precipitation in 10% trichloracetic acid and segmented polymorphs (polymorphs with more than redissolving the precipitate in N sodium hydroxide. The five nuclear lobes) were more frequent in the stained content of M protein in urine was estimated after electro- peripheral blood films ofgroup I, less frequent in those phoresis of concentrated urine by the method used to III. estimate serum M protein. of group II, and rarely present in those of group RELATION OF MEGALOBLASTIC HAEMOPOIESIS TO OTHER PRODUCTION OF M PROTEIN An estimate of the DAILY all of the 32 daily output of M protein was made using the following HAEMATOLOGICAL FINDINGS Nearly (30) assumptions. It has been shown that YA myeloma glob- patients were anaemic at the time of the present ulins have a shorter half life (mean 6-4 days) than yo studies (Table I). There was no direct correlation J Clin Pathol: first published as 10.1136/jcp.20.5.699 on 1 September 1967.
Load more

Recommended publications
  • Cytology of Myeloma Cells
    J Clin Pathol: first published as 10.1136/jcp.29.10.916 on 1 October 1976. Downloaded from J. clin. Path., 1976, 29, 916-922 Cytology of myeloma cells F. G. J. HAYHOE AND ZOFIA NEUMAN1 From the Department of Haematological Medicine, Cambridge University SYNOPSIS A cytological, cytochemical, and cytometric study of plasma cells from 195 cases of multiple myeloma showed that, contrary to earlier reports, flaming cells, thesaurocytes, and intra- nuclear inclusions are not confined to IgA-secreting cases but are common also in IgG and Bence Jones varieties of myeloma. IgA-secreting cells are not larger, nor do they have a lower nuclear- cytoplasmic ratio than other myeloma cells. On average, for a given mass of tumour, Bence-Jones, IgG, and IgA varieties of myeloma produce amounts of paraprotein in the ratio 1 to 1 6 to 2-7. In 1961 Paraskevas et al reported a correlation the results of a larger scale survey carried out some between the morphological features of plasma cells years ago but previously unpublished. in myeloma and the type of immunoglobulin secreted. The cases studied included 12 with y1A Material and methods (f2A, IgA) myeloma, 30 with y (IgG) myeloma, and six myelomas without M protein (probably Bence The study was performed on bone marrow smearscopyright. Jones myelomas). Flaming cells, thesaurocytes, and from 200 consecutive patients newly entered into a intranuclear, PAS-positive inclusion bodies were comparative trial of treatments in myeloma, under found only in cases of IgA myeloma, and flaming the auspices of the Medical Research Council. Five cells especially were present in most cases and in patients were subsequently excluded as not confirmed high percentage in several.
    [Show full text]
  • Evidence-Based Practice Center Systematic Review Protocol
    Evidence-based Practice Center Systematic Review Protocol Project Title: Serum-Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias I. Background and Objectives for the Systematic Review Plasma cell dyscrasias (PCDs) are a spectrum of disorders characterized by the expansion of a population of monoclonal bone-marrow plasma cells that produce monoclonal immunoglobulins.1 At the benign end of the spectrum is monoclonal gammopathy of undetermined significance (MGUS), where the plasma-cell clone usually does not expand. Multiple myeloma (MM) is a plasma cell disorder at the malignant end of the spectrum and is characterized by the neoplastic proliferation of a clone of plasma cells in the bone marrow with resulting end-organ damage, including skeletal destruction (lytic bone lesions), hypercalcemia, anemia, and renal insufficiency. Whereas monoclonal plasma cells generally secrete intact immunoglobulin, in about 20 percent of patients with MM these cells only produce light-chain monoclonal proteins (i.e., light-chain multiple myeloma [LCMM], formerly known as Bence Jones myeloma) and in 3 percent of patients they secrete neither light- nor heavy-chain monoclonal proteins that are detectable by immunofixation (i.e., nonsecretory multiple myeloma [NSMM]).1 In two-thirds of patients with NSMM, a monoclonal protein can be identified by the serum-free light chain (SFLC) assay. Patients with LCMM develop complications related to tissue deposition of light chains, including amyloidosis. Amyloid light-chain (AL) amyloidosis is the most common form of systemic amyloidosis seen in the United States and is characterized by a relatively stable, slow-growing plasma-cell clone that secretes light-chain proteins that form Table 1: Diagnostic criteria and clinical course of selected plasma cell dyscrasias (PCDs)2 Disorder Disease Definition Clinical Course Monoclonal gammopathy of .
    [Show full text]
  • Canine Multiple Myeloma
    Canine Multiple Myeloma Meredith Maczuzak, DVM; Kenneth S. Latimer, DVM, PhD; Paula M. Krimer, DVM, DVSc; and Perry J. Bain, DVM, PhD Class of 2003 (Maczuzak) and Department of Pathology (Latimer, Krimer, Bain), College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7388 Introduction Multiple myeloma or plasma cell myeloma, is a neoplasm of well- differentiated B cell lymphocytes typically originating from the bone marrow. Neoplastic cells can metastasize widely, having a predilection for bone and resulting in osteolysis. The malignant transformation of a single B cell can secrete a homogenous immunoglobulin product known as paraprotein, which will mimic the structure of normal immunoglobulins. Overabundant production of paraprotein, consisting of any of the immunoglobulin classes, will appear as a sharp, well-defined peak or monoclonal gammopathy on serum electrophoresis. The most frequently encountered multiple myelomas secrete IgG or IgA paraproteins, however IgM myelomas (macroglobulinemia) have also been diagnosed in companion animals. Light chain disease is caused by plasma cell overproduction of the light chain segment of the immunoglobulin complex, consisting of either the lambda or kappa light chain. These proteins are referred to as Bence-Jones proteins and are the most commonly observed immunoglobulin fragments in the monoclonal gammopathies.2 There are rare instances where a malignant plasma cell neoplasm will be nonsecretory. These tumors occur in approximately 1% of all cases of multiple myeloma and are referred
    [Show full text]
  • Chapter 7: Hematologic Disorders and Kidney Disease
    Chapter 7: Hematologic Disorders and Kidney Disease Ala Abudayyeh, MD,* and Kevin Finkel, MD, FACP, FASN, FCCM*† *Division of General Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas; and †UTHealth Science Center at Houston Medical School, Department of Medicine, Division of Renal Diseases and Hypertension, Houston, Texas MULIPLE MYELOMA chains precipitate with Tamm-Horsfall protein (THP) secreted by the thick ascending limb of the Pathogenesis loop of Henle and produce casts in the distal tubule. Multiple myeloma (MM) is a hematologic malig- Decreased GFR may increase the concentration of nancy involving the pathologic proliferation of light chains in the distal tubule and enhance the terminally differentiated plasma cells. It is the formation of casts. Therefore, hypercalcemia, vol- second most common hematologic malignancy ume depletion, diuretics, and nonsteroidal anti- behind non-Hodgkin lymphoma, with an annual inflammatory drugs can exacerbate renal injury. incidence of 4–7 cases per 100,000 in the United In some cases of AKI associated with MM, cast States. Clinical symptoms are due to osteolysis of formation is rare on renal biopsy. Instead, renal the bone, suppression of normal hematopoiesis, injury is attributed to the direct toxic effects of and the overproduction of monoclonal immuno- urinary free light chains (FLCs) on proximal tubule globulins that deposit in organ tissues. Clinical cells (5,6). After reabsorption, lysosomal degrada- symptoms include bone pain and fractures, anemia, tion of FLCs can activate the NF-kB pathway lead- infections, hypercalcemia, edema, heart failure, and ing to oxidative stress with an inflammatory renal disease. response, apoptosis, and fibrosis.
    [Show full text]
  • Intranuclear Inclusions in Myeloma Patient
    Published online: 2021-05-24 Letter to Editor Pathologist’s Feast: Intranuclear Inclusions in Myeloma Patient Sir, aspiration [Figure 2]. Plasma cells showed Dutcher body We present a case of a 36‑year‑old female admitted in bone marrow aspiration [Figure 3] as periodic acid– in hospital with complaints of pain in sacral region Schiff positive intranuclear inclusion [Figure 4]. The bone radiating toward right lower limb for 1 month. Laboratory marrow biopsy showed loss of normal architecture with examination revealed hemoglobin 8.1 g/dL, red blood packed marrow studded by plasma cells [Figure 5]. cell count – 2.61 × 109/mm3, white blood cell count Multiple myeloma account for 1% of all cancers and 16.16 × 103/mm3, and platelet count 299 × 109/mm3. The approximately 10% of all hematological malignancies.[1] The differential showed polymorphs – 74%, lymphocytes – 22%, eosinophils – 1%, and monocytes – 3%. Peripheral blood peak incidence is seventh decade, and it is quite rare, below smear showed rouleaux formation in red blood cells. The 40 years of age. The clinical and biological characteristics serum biochemistry showed blood urea – 54 mg/dl and of multiple myeloma in young patients are similar to those [2] creatinine – 3.8 mg/dl, angiotensin converting enzyme in elderly as in literature in studies by Usha et al. and [3] level – 64.25 U/L, and serum calcium – 13.3 mg/dl. Liver Bladé et al. The above case shows ditcher body inclusions function tests and serum electrolytes were normal and in plasma cells on bone marrow aspiration. HIV and HBsAg were nonreactive.
    [Show full text]
  • Successful Autologous Peripheral Blood Stem Cell Harvest and ­Transplantation After Splenectomy in a Patient with Multiple ­Myeloma with Hereditary Spherocytosis
    International Journal of Myeloma 8(3): 11–15, 2018 CASE REPORT ©Japanese Society of Myeloma Successful autologous peripheral blood stem cell harvest and transplantation after splenectomy in a patient with multiple myeloma with hereditary spherocytosis Daisuke FURUYA1,4, Rikio SUZUKI1,4, Jun AMAKI1, Daisuke OGIYA1, Hiromichi MURAYAMA1,2, Hidetsugu KAWAI1, Akifumi ICHIKI1,3, Sawako SHIRAIWA1, Shohei KAWAKAMI1, Kaito HARADA1, Yoshiaki OGAWA1, Hiroshi KAWADA1 and Kiyoshi ANDO1 Hereditary spherocytosis (HS) is the most common inherited red cell membrane disorder worldwide. We herein report a 58-year-old male HS patient with mild splenomegaly who developed symptomatic multiple myeloma (MM). Autologous stem cell transplantation (ASCT) was considered to be adopted against MM, although there was a possibility of splenic rupture following stem cell mobilization. Therefore, splenectomy was performed prior to stem cell harvest, and he was able to safely mobilize sufficient CD34+ cells with G-CSF and plerixafor and undergo ASCT. This case suggests that stem cell mobilization after splenectomy is safe and effective in HS patients complicated with malignancies. Key words: multiple myeloma, hereditary spherocytosis, splenectomy, autologous peripheral blood stem cell harvest Introduction Consolidation with melphalan-based HDT followed by ASCT is still the standard treatment option for transplant-eligible Multiple myeloma (MM) is characterized by clonal prolifera- patients with MM, leading to higher complete response rates tion of abnormal plasma cells in the bone marrow (BM) micro- and increased progression-free survival and overall survival environment, monoclonal protein in the blood and/or urine, compared with conventional chemotherapy regimens [2]. bone lesions, and immunodeficiency [1]. In recent years, the Importantly, the emergence of novel agent-based therapy introduction of high-dose chemotherapy (HDT) and autol- combined with ASCT has revolutionized MM therapy [2].
    [Show full text]
  • Clinical Hematology 1
    CLINICAL HEMATOLOGY 1 CLINICAL HEMATOLOGY Editor Gamal Abdul Hamid, MD,PhD Associate Professor Faculty of Medicine and Health Sciences University of Aden CLINICAL HEMATOLOGY 2 PREFACE Clinical Hematology, first edition is written specifically for medical students, the clinician and resident doctors in training and general practioner. It is a practical guide to the diagnosis and treatment of the most common disorders of red blood cells, white blood cells, hemostasis and blood transfusion medicine. Each disease state is discussed in terms of the pathophysiology, clinical and paraclinical features which support the diagnosis and differential diagnosis. We bring together facts, concepts, and protocols important for the practice of hematology. In addition this book is also supported with review questions and quizzes. G.A-H 2012 CLINICAL HEMATOLOGY 3 CONTENTS Preface 1. Hematopoiesis 7 2. Anemia 26 3. Iron Deficiency Anemia 32 4. Hemolytic Anemia 41 5. Sickle Cell Hemoglobinopathies 49 6. Thalassemia 57 7. Hereditary Hemolytic Anemia 63 8. Acquired Hemolytic Anemia 68 9. Macrocytic Anemia 75 10. Bone Marrow Failure, Panctopenia 87 11. Spleen 95 12. Acute Leukemia 99 13. Chronic Myeloproliferative Disorders 125 14. Chronic Lymphoproliferative Disorders 137 15. Malignant Lymphoma 147 16. Multiple Myeloma and Related Paraproteinemia 171 17. Hemorrhagic Diseases 179 18. Transfusion Medicine 201 19. Bone Marrow Transplantations 214 CLINICAL HEMATOLOGY 4 Appendices: I. Hematological Tests and Normal Values 221 II. CD Nomenclature for Leukocytes Antigen 226 III. Cytotoxic Drugs 228 IV. Drugs Used in Hematology 230 Glossary 232 Answers 246 Bibliography 247 CLINICAL HEMATOLOGY 5 CLINICAL HEMATOLOGY 6 HEMATOPOIESIS 1 All of the cells in the peripheral blood have finite life spans and thus must be renewed continuously.
    [Show full text]
  • © 2016 First Aid for the USMLE Step 1
    Index A Abscess, 442 vs. aspirin, in pediatric patients, 446 Achondroplasia, 426 Abacavir, 184 Absence seizures, 494 free radical injury and, 221 autosomal dominance of, 71 for HIV, 186 drug therapy for, 500 necrosis caused by, 252 chromosome associated with, 75 Abciximab, 214, 407 treatments for, 638 for osteoarthritis, 430 endochondral ossification in, 425 thrombogenesis and, 385 Absolute risk reduction (ARR), 34, for tension headaches, 494 AChR (acetylcholine receptor), 229 Abdominal aorta, 342 646 toxicity effects, 446 Acid-base physiology, 543 atherosclerosis in, 286, 645 Absorption disorders, anemia caused toxicity treatment for, 251 Acidemia, 543 bifurcation of, 609 by, 388 Acetazolamide, 254, 557 diuretic effect on, 558 498 92 Abdominal aortic aneurysm, 286 Abuse for glaucoma, Acidic amino acids, metabolic acidosis caused by, 543 Acidosis, 543 Abdominal colic confidentiality exceptions and, 41 in nephron physiology, 537 contractility in, 267 lead poisoning as cause, 389 dependent personality disorder for pseudotumor cerebri, 471 hyperkalemia caused by, 542 Abdominal distension and, 519 site of action, 556 Acid phosphatase, in neutrophils, 378 duodenal atresia as cause, 338 Acalculia, 464 Acetoacetate, metabolism of, 102 Acid reflux Abdominal pain Acamprosate Acetone breath, in diabetic esophageal strictures and, 354 Budd-Chiari syndrome as for alcoholism, 523, 638 ketoacidosis, 331 esophagitis and, 354 cause, 368, 630 diarrhea caused by, 252 Acetylation, 57 H blockers for, 374 cilostazol/dipyridamole as Acanthocytes, 386 2 Acetylcholine
    [Show full text]
  • Myeloma for Diagnosticians
    Myeloma for Diagnosticians Dr Mamta Garg Consultant Haematologist What is Myeloma? Malignant disorder of plasma cells • an excess of abnormal plasma cells >10% • paraprotein in the serum and/or urine • End organ affection CRAB, SLiM CRAB Diagnosis: Paraprotein or M protein SPEP CRAB and now “Slim CRAB” • Myeloma defining events or Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: – C: Hypercalcaemia: serum calcium >0·25 mmol/L higher than the upper limit of normal or >2·75 mmol/L R: Renal insufficiency – R: Creatinine clearance <40 mL per min or serum creatinine >177 μmol/L (>2 mg/dL) – A: Anaemia: Hb >20 g/L below usual Hb, or a Hb <100 g/L – B: Bone lesions: one or more osteolytic lesions on XR, CT or PET-CT • Any one or more of the following biomarkers of malignancy: – S (M-spike) : Clonal bone marrow plasma cell percentage* ≥60% – Li: Involved:uninvolved serum free light chain ratio≥100 (or <0.01) – M: >1 focal lesions on MRI studies of 1 cm in size Rajkumar et al. Lancet Oncol. 2014 Nov;15(12):e538-48 Asymptomatic/Smouldering Myeloma • M protein present in serum and/or urine • Plasma cells >10% in the marrow • No CRABs • It carries a higher risk of progression to frank multiple myeloma (10% per year the first 5 years) compared with MGUS ISS, now Revised ISS or R-ISS LDH and FISH analysis on BM sample mandatory ISS STAGE CRITERIA RISK CRITERIA I B2M <3.5 Albumin >35 Normal Normal Serum LDH <upper limit of normal II B2M >3.5 but <5.5 or Albumin <35 High High serum
    [Show full text]
  • Open Full Page
    3IULTIPLE MYELOMA A REPORTOF FIVECASES ERNEST SCOTT, M.D., F. M. STANTON, M.D., AND MARY OLIVER, MA. (From the Department of Pathology, Ohio State University) In 1848 Sir Henry Bence-Jones aiid Sir James Watson pre- sented a paper entitled, “On a New substance Occurring in the Urine of a Patient with Mollitis-ossium,” a “substance” now known as the Bence-Jones bodies, frequeiitly found in the urine of patients with multiple myeloma. The clinical discussion of this same case mas presented in 1850 by McIntyre. In 1873 von Rustizky, in his histological studies of the disease, recognized its involvement of the bone marrow and gave it the name of multiple myeloma. IGililer, in 1889, ~lsopresented a clinical description of the disease and inasmuch as he, rather than McIntyre, has often been credited with the first clinical presentation, the term “Kahler ’s disease” is frequently encountered in the older litera- ture. In 1920 Wallgren reported 120 cases with histological verifica- tion. In 1928 Geschickter and Copeland (l), from the surgical pathological material of the Johns Hopkins Hospital, reported a series of 13 cases, together with a complete review of all available cases in the literature, making a total of 425 cases. Since the publication of this comprehensive article with its discussion of the clinical and structural characteristics of the disease, we have been able to collect from the more recent literature 30 cases of multiple myeloma. To these we add 5 cases from among about 4400 au- topsies in our own series. Grouped by years, the additional cases are : 1927 : Lewis (2), Meyeriling (3), Kleine (4) ; 1928: Battaglia (5), Hcilmann (6), Barr (7),Durman (8), Short iind Crawford (9) ; 1929: Hewitt (10) (5 cases), Stone (ll), Cappel1 (12) (2 cases), Rogers (13), Hub- bard and Case (14) ; 1930: Perla aiid Hutner (15) (2 cases), Cabot (16), Geschickter (17), Freund (18) ; 1931: Cabot (19), Porchownik (20), Jackson et a1 (21) (5 cases).
    [Show full text]
  • Pathology Course
    Pathology Course Kindly Sponsored by: Edited by: Michelle Kunc, Jhia Teh, Sally Barker and Yvonne Tsitsiou 1 Introduction The Medical Education Society (MedED) was established in 2004 by three students who were keen to develop schemes whereby senior students tutor younger ones - ‘peer-to- peer’ learning. It was decided that teaching would be outside the formal curriculum and the topics covered would reflect learning needs identified by members of the society and student body. This year we have coordinated PACES and Pathology revision courses, which are being delivered by past ICSM students. We hope you enjoy our Year 5 events and find their content useful for your revision. We would like to thank all the doctors involved in the production of this guide for their support and for taking time out of the schedules to come back and teach us. We would also like to thank the previous MedED guide editors: • 2016-2017: Daniel Campioni-Norman, Rhys Smith, Helen-Cara Younan and Rebekah Judge • 2017-2018: Charlie Caird, Stephanie EzeKwe, Mohammad Fallaha, Samyukta Sundar • 2018-2019: Sophia von Widekind, Lasith Ranasinghe, Daniel Huddart, Alex Huddart If you have any questions please contact us at [email protected]. Please note: MedED does not represent the ICSM Faculty or Student Union. This guide has been produced by students and the Pathology Course lecturers. We have made every effort to ensure that the following information is accurate and reliable. However, this guide should not be used to replace formal ICSM teaching and education
    [Show full text]
  • View the 2019 Index
    Index A Abnormal uterine bleeding (AUB), heart failure, 311 Achondroplasia, 454 A-a gradient 618, 619 hypertension, 319 chromosome disorder, 64 in elderly, 654 adenomyosis, 634 naming convention for, 253 endochondral ossification in, 450 with hypoxemia, 654, 655 anemia with, 410 preload/afterload effects, 282 inheritance, 60 restrictive lung disease, 661 Asherman syndrome, 634 teratogenicity, 600 AChR (acetylcholine receptor), 229 Abacavir, 201, 203 leiomyoma (fibroid), 634 Acetaldehyde, 72 Acid-base physiology, 580 Abciximab, 122 polyps (endometrial), 634 Acetaldehyde dehydrogenase, 70, 72 Acidemia, 580 Glycoprotein IIb/IIIa inhibitors, thecoma, 632 Acetaminophen, 474 diuretic effect on, 595 429 ABO blood classification, 397 vs. aspirin for pediatric patients, 474 Acid-fast oocysts, 177 thrombogenesis and, 403 newborn hemolysis, 397 free radical injury and, 210 Acid-fast organisms, 125, 140, 155 Abdominal aorta, 357 Abruptio placentae, 626 hepatic necrosis from, 249 Acidic amino acids, 81 atherosclerosis in, 305, 687 cocaine use, 600 N-acetylcysteine for overdose, 671 Acid maltase, 86 bifurcation of, 649 preeclampsia, 629 for osteoarthritis, 458 Acidosis, 578, 580 Abdominal aortic aneurysm, 306 Abscess, 470 toxicity effects, 474 contractility in, 282 Abdominal colic acute inflammation and, 215 toxicity treatment for, 247 hyperkalemia with, 578 lead poisoning, 411 lung, 670 Acetazolamide, 252, 539, 594 Acid phosphatase in neutrophils, 398 Abdominal pain Absence seizures idiopathic intracranial Acid reflux bacterial peritonitis, 384 characteristics
    [Show full text]